MedDevNews, Q1 2024

The first quarter of 2024 showed continued softness across the MedTech M&A and private financing market, with a decline across all categories compared to 2023. However, the industry is gearing up for an increase in activity in late 2024 and 2025, especially with technology-driven, highly differentiated OEMs and PE-backed CMOs that emerged from the post-pandemic slump as stronger organizations. Read the full report here.

For more insights on sector trends or to discuss your strategic priorities, contact one of our healthcare experts.

Healthcare Check-Up, Q1 2024

Improving capital markets conditions during 2024 should boost M&A activity overall. We are sensing a more optimistic view around transactions beginning to take shape, with more sponsors actively looking to deploy capital and debt financing easier to come by.

Commercial banks have returned to the market after a lull in 2023. We expect to see continuing activity in retail and specialty pharmacy throughout the year as large owners of assets continue to restructure their portfolios. We also expect the hospital, clinic and surgery center sectors to remain active. Significant activity in staffing is likely to be delayed due to continuing post-Covid fallout in shifts and bill rates.

Read the full report here.